Selecta Biosciences Inc. [SELB] stock was sold by Brunn Carsten at the price of US$4470.0

0
4

Selecta Biosciences Inc.’s filing revealed that its President and CEO Brunn Carsten unloaded Company’s shares for reported $4470.0 on Sep 28. In the deal valued at $1.66 per share,2,692 shares were sold. As a result of this transaction, Brunn Carsten now holds 537,867 shares worth roughly $ 0.88 million.


Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report

Sponsored


Then, Brunn Carsten sold 4,768 shares, generating $8,810 in total proceeds. Upon selling the shares at $1.85, the President and CEO now owns 540,559 shares.

Before that, COX CARRIE SMITH bought 130,000 shares. Selecta Biosciences Inc. shares valued at $149,799 were divested by the Director at a price of $1.15 per share. As a result of the transaction, COX CARRIE SMITH now holds 212,881 shares, worth roughly $0.35 million.

Needham reiterated its Selecta Biosciences Inc. [SELB] rating to a Buy in a research note published on Friday, June 14, 2022; the price target was $5. PT values the company’s stock at a premium of 67.2 to its Friday closing price. A number of analysts have revised their coverage, including SVB Leerink’s analysts, who began to cover the stock in early June with a ‘”an Outperform”‘ rating. BTIG Research began covering SELB with “Buy” recommendation on June 15, 2021. Mizuho revised its rating on January 26, 2021. It rated SELB as “a Buy” which previously was an “a Neutral”.

Price Performance Review of SELB

On Friday, Selecta Biosciences Inc. [NASDAQ:SELB] saw its stock fall -2.96% to $1.64. On the same session, the stock had its day’s lowest price of $1.585, but rose to a high of $1.68. Over the last five days, the stock has lost -3.53%. Selecta Biosciences Inc. shares have fallen nearly -49.69% since the year began. Nevertheless, the stocks have fallen -58.59% over the past one year. While a 52-week high of $4.34 was reached on 01/03/22, a 52-week low of $0.65 was recorded on 05/11/22. SMA at 50 days reached $1.6878, while 200 days put it at $1.5568. A total of 0.81 million shares were traded, compared to the trading of 0.66 million shares in the previous session.

Levels Of Support And Resistance For SELB Stock

The 24-hour chart illustrates a support level at 1.5900, which if violated will result in even more drops to 1.5400. On the upside, there is a resistance level at 1.6850. A further resistance level may holdings at 1.7300. The Relative Strength Index (RSI) on the 14-day chart is 49.73, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.0426, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 40.00%. Stochastics %K at 63.56% indicates the stock is a holding.

How much short interest is there in Selecta Biosciences Inc.?

A steep rise in short interest was recorded in Selecta Biosciences Inc. stocks on Jul 14, 2022, dropping by -2.26 million shares to a total of 6.36 million shares. Yahoo Finance data shows the prior-month short interest on Jun 14, 2022 was 8.62 million shares. There was a decline of -35.53%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 6.30% of the overall stock float, the days-to-cover ratio (short ratio) fell to 2.25.

Selecta Biosciences Inc. [SELB] – Who Are The Largest Shareholders?

In filings from Mangrove Partners, it is revealed that the company now owns 7,260,419 shares, or roughly 4.75% of the outstanding SELB shares. Additionally, The Vanguard Group, Inc. decreased -2.13% of its stake after which the total value it holdings stand at $8,991,654, while Invus Public Equities Advisors LL added 22.08% of its stake to hold $8.01 million in the firm. Over the last quarter, Endurant Capital Management LP purchased 1,159,677 shares of Selecta Biosciences Inc., while Ecor1 Capital LLC bought 3,500,000 shares. At present, BlackRock Fund Advisors is holding 2,274,564 shares valued at $3.73 million. BVF Partners LP owned 1,723,133 shares of the company at the time of its most recent 13F filing, worth $2.83 million.

According to FactSet, Selecta Biosciences Inc.’s share price will average $6.86 in the next year, based on opinions of analysts polled by the firm. This is up nearly 314.2 percent from its previous closing price of $1.69. Analysts expect Selecta Biosciences Inc. stock to reach the higher price of $10.00, while the lowest price estimate is $4.00. However, 8 analysts have rated SELB stock as a Buy in their predictions for 2022.

LEAVE A REPLY

Please enter your comment!
Please enter your name here